{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:52:48Z","timestamp":1764510768173},"reference-count":21,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2021]]},"DOI":"10.1620\/tjem.254.101","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T22:08:23Z","timestamp":1624054103000},"page":"101-105","source":"Crossref","is-referenced-by-count":6,"title":["Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine"],"prefix":"10.1620","volume":"254","author":[{"given":"Haruya","family":"Okamoto","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine"},{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Kamitsuji","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Komori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Almond, L.M., Charalampakis, M., Ford, S.J., Gourevitch, D. &amp; Desai, A. (2017)  Myeloid sarcoma: presentation, diagnosis, and treatment.  <i>Clin. Lymphoma Myeloma Leuk.<\/i>, 17, 263-267.","DOI":"10.1016\/j.clml.2017.02.027"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Castelli, A., Mosca-Siez, M.L., Riccomagno, P., Patriarca, A., Liscia, D. &amp; Conconi, A. (2018)  Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report.  <i>Ann. Hematol.<\/i>, 97, 1485-1486.","DOI":"10.1007\/s00277-018-3314-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Daver, N., Boddu, P., Garcia-Manero, G., Yadav, S.S., Sharma, P., Allison, J. &amp; Kantarjian, H. (2018)  Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.  <i>Leukemia<\/i>, 32, 1094-1105.","DOI":"10.1038\/s41375-018-0070-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Evers, D., Bar, B., Gotthardt, M. &amp; van der Velden, W. (2018)  Activity of decitabine in pericardial myeloid sarcoma.  <i>Int. J. Hematol.<\/i>, 108, 121-122.","DOI":"10.1007\/s12185-018-2470-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Goodyear, O., Agathanggelou, A., Novitzky-Basso, I., Siddique, S., McSkeane, T., Ryan, G., Vyas, P., Cavenagh, J., Stankovic, T., Moss, P. &amp; Craddock, C. (2010)  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.  <i>Blood<\/i>, 116, 1908-1918.","DOI":"10.1182\/blood-2009-11-249474"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Gornicec, M., Wolfler, A., Stanzel, S., Sill, H. &amp; Zebisch, A. (2017)  Evidence for a role of decitabine in the treatment of myeloid sarcoma.  <i>Ann. Hematol.<\/i>, 96, 505-506.","DOI":"10.1007\/s00277-016-2870-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Kanate, A.S., Vos, J. &amp; Chargualaf, M.J. (2019)  Venetoclax for refractory myeloid sarcoma.  <i>J. Oncol. Pract.<\/i>, 15, 413-415.","DOI":"10.1200\/JOP.18.00753"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Katagiri, T., Ushiki, T., Masuko, M., Tanaka, T., Miyakoshi, S., Fuse, K., Shibasaki, Y., Takizawa, J., Aoki, S. &amp; Sone, H. (2017)  Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: a case report and literature review.  <i>Medicine <\/i>(<i>Baltimore<\/i>), 96, e7975.","DOI":"10.1097\/MD.0000000000007975"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kawamoto, K., Miyoshi, H., Suzuki, T., Kiyasu, J., Yokoyama, S., Sasaki, Y., Sone, H., Seto, M., Takizawa, J. &amp; Ohshima, K. (2018)  Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.  <i>Hematol. Oncol.<\/i>, 36, 591-599.","DOI":"10.1002\/hon.2506"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Lindblad, K.E., Goswami, M., Hourigan, C.S. &amp; Oetjen, K.A. (2017)  Immunological effects of hypomethylating agents.  <i>Expert Rev. Hematol.<\/i>, 10, 745-752.","DOI":"10.1080\/17474086.2017.1346470"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Liu, B., Guo, Y., Deng, L., Qiao, Y. &amp; Jian, J. (2020)  The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.  <i>Hematology<\/i>, 25, 414-423.","DOI":"10.1080\/16078454.2020.1843752"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Minoia, C., de Fazio, V., Scognamillo, G., Scattone, A., Maggialetti, N., Ferrari, C. &amp; Guarini, A. (2019)  Long-lasting remission in de novo breast myeloid sarcoma treated with decitabine and radiotherapy.  <i>Diagnostics <\/i>(<i>Basel<\/i>), 9, 84.","DOI":"10.3390\/diagnostics9030084"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Modi, G., Madabhavi, I., Panchal, H., Patel, A., Anand, A., Parikh, S., Jain, P., Revannasiddaiah, S. &amp; Sarkar, M. (2015)  Primary vaginal myeloid sarcoma: a rare case report and review of the literature.  <i>Case Rep. Obstet. Gynecol.<\/i>, 2015, 957490.","DOI":"10.1155\/2015\/957490"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Nahas, M.R., Stroopinsky, D., Rosenblatt, J., Cole, L., Pyzer, A.R., Anastasiadou, E., Sergeeva, A., Ephraim, A., Washington, A., Orr, S., McMasters, M., Weinstock, M., Jain, S., Leaf, R.K., Ghiasuddin, H., et al.  (2019)  Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine.  <i>Br. J. Haematol.<\/i>, 185, 679-690.","DOI":"10.1111\/bjh.15818"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Santourlidis, S., Trompeter, H.I., Weinhold, S., Eisermann, B., Meyer, K.L., Wernet, P. &amp; Uhrberg, M. (2002)  Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells.  <i>J. Immunol.<\/i>, 169, 4253-4261.","DOI":"10.4049\/jimmunol.169.8.4253"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Serrao, A., Loglisci, G., Salaroli, A., Zacheo, I., Alimena, G.,  &amp;  Breccia, M. (2013)  Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization.  <i>Leuk. lymphoma<\/i>, 54, 411-412.","DOI":"10.3109\/10428194.2012.702905"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Singh, S.N., Cao, Q., Gojo, I., Rapoport, A.P. &amp; Akpek, G. (2012)  Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.  <i>Bone Marrow Transplant.<\/i>, 47, 1008-1009.","DOI":"10.1038\/bmt.2011.210"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Stahl, M. &amp; Goldberg, A.D. (2019)  Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets.  <i>Curr. Oncol. Rep.<\/i>, 21, 37.","DOI":"10.1007\/s11912-019-0781-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Wang, H.Q. &amp; Li, J. (2016)  Clinicopathological features of myeloid sarcoma: report of 39 cases and literature review.  <i>Pathol. Res. Pract.<\/i>, 212, 817-824.","DOI":"10.1016\/j.prp.2016.06.014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M.R., Davanlou, M., Geng, Q.R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., Parmar, S., Cortes, J., Kantarjian, H. &amp; Garcia-Manero, G. (2014)  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.  <i>Leukemia<\/i>, 28, 1280-1288.","DOI":"10.1038\/leu.2013.355"},{"key":"21","unstructured":"Yilmaz, A.F., Saydam, G., Sahin, F. &amp; Baran, Y. (2013)  Granulocytic sarcoma: a systematic review.  <i>Am. J. Blood Res.<\/i>, 3, 265-270."}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/254\/2\/254_101\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T04:29:42Z","timestamp":1624076982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/254\/2\/254_101\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.254.101","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}